A detailed history of Morgan Stanley transactions in Arcellx, Inc. stock. As of the latest transaction made, Morgan Stanley holds 757,152 shares of ACLX stock, worth $66.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
757,152
Previous 545,077 38.91%
Holding current value
$66.7 Million
Previous $30.1 Million 110.19%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$50.91 - $86.61 $10.8 Million - $18.4 Million
212,075 Added 38.91%
757,152 $63.2 Million
Q2 2024

Oct 17, 2024

SELL
$49.74 - $66.98 $7.54 Million - $10.2 Million
-151,685 Reduced 21.77%
545,077 $30.1 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $7.54 Million - $10.2 Million
-151,685 Reduced 21.77%
545,077 $30.1 Million
Q1 2024

Oct 17, 2024

BUY
$51.85 - $73.49 $7.86 Million - $11.1 Million
151,685 Added 27.83%
696,762 $48.5 Million
Q1 2024

Aug 16, 2024

BUY
$51.85 - $73.49 $1.22 Million - $1.73 Million
23,477 Added 3.49%
696,762 $48.5 Million
Q1 2024

May 15, 2024

BUY
$51.85 - $73.49 $1.22 Million - $1.73 Million
23,477 Added 3.49%
696,762 $48.5 Million
Q4 2023

Aug 16, 2024

BUY
$31.75 - $57.99 $4.07 Million - $7.43 Million
128,208 Added 23.52%
673,285 $37.4 Million
Q4 2023

Feb 13, 2024

BUY
$31.75 - $57.99 $18 Million - $32.9 Million
568,027 Added 539.65%
673,285 $37.4 Million
Q3 2023

Nov 15, 2023

SELL
$31.51 - $37.4 $5.48 Million - $6.5 Million
-173,853 Reduced 62.29%
105,258 $3.78 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $4.69 Million - $8.01 Million
170,713 Added 157.49%
279,111 $8.83 Million
Q1 2023

May 15, 2023

SELL
$26.92 - $33.94 $406,411 - $512,392
-15,097 Reduced 12.22%
108,398 $3.34 Million
Q4 2022

Feb 14, 2023

BUY
$17.18 - $33.0 $460,252 - $884,070
26,790 Added 27.7%
123,495 $3.83 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $326,098 - $431,146
19,562 Added 25.36%
96,705 $1.82 Million
Q2 2022

Oct 27, 2022

BUY
$7.21 - $24.43 $548,717 - $1.86 Million
76,105 Added 7331.89%
77,143 $1.4 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $548,717 - $1.86 Million
76,105 Added 7331.89%
77,143 $1.4 Million
Q1 2022

Oct 27, 2022

SELL
$12.97 - $19.14 $987,081 - $1.46 Million
-76,105 Reduced 98.65%
1,038 $14,000
Q1 2022

May 13, 2022

BUY
$12.97 - $19.14 $13,462 - $19,867
1,038 New
1,038 $14,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.86B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.